New cancer drug injected directly into tumors shows early promise
NCT ID NCT05727839
Summary
This early-stage study tested the safety and initial effectiveness of an experimental immunotherapy called JCXH-211. The drug was injected directly into tumors of 19 patients with advanced solid cancers who had no other treatment options. The main goal was to see if the treatment was safe and to find the right dose, while also checking if it helped slow or shrink tumors by boosting the body's immune system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangdong, Guangzhou, 510060, China
-
The George Washington Medical Faculty Associates
Washington D.C., District of Columbia, 20037, United States
Conditions
Explore the condition pages connected to this study.